BMY News and Press, Bristol-Myers Squibb Company From 06/21/24

Approval based on results from the Phase 1/2 KRYSTAL-1 study where KRAZATI in combination with cetuximab showed an objective response rate of 34% in pretreated patients with locally advanced or metastatic CRC harboring a KRAS G12C mutation 1 Second FDA approval for KRAZATI - r...

2024-06-21 14:06:48 ET More on Bristol-Myers Squibb Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least Bristol-Myers Squibb: Could This Be A Value Trap? (Technical Analysis) Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthca...

2024-06-21 07:25:03 ET More on Bristol-Myers Squibb Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least Bristol-Myers Squibb: Could This Be A Value Trap? (Technical Analysis) Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthca...

Validation is based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of Opdivo to evaluate and demonstrate noninferior pharmacokinetics and efficacy vs. its intravenous formulation Application seeks approval for subcutaneous nivolumab formulation...

2024-06-20 10:30:00 ET June 20, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform, releases an industry snapshot looking at the future treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (Nasdaq:AEMD ), a medical therapeutic company f...

2024-06-20 08:46:01 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – This year’s 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for...

Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2024 on Friday, July 26, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors a...

2024-06-20 06:53:11 ET Summary Corvus Pharmaceuticals has shown positive growth and maturity over the past six months, with new leadership and increased clinical trial activity. The company is expanding its label and IP developments, with trials in oncology and immunology, as well...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – This year’s 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for cancer patients around the w...

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024. Mr. McMullen will serve as a member of the Audit Committee of the Board of Directors. “We are pleased to welcome Mr....